ClinicalTrials.gg
CompletedNCT04284761Biolen-PCUpdated Jun 24, 2024

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

A Phase 1 interventional study of Bicalutamide implant in Prostate Adenocarcinoma and Lower Urinary Tract Symptoms, sponsored by Alessa Therapeutics Inc.. Completed at 4 sites in 3 countries. Open to male participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Alessa Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
35 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lower Urinary Tract Symptoms with a site in Australia — 1 open to participants now, 4 under way, none of them phase 3. Lower Urinary Tract Symptoms · Australia.

Enrollment
10th of 10
17 · median 122
Started
2020
the only one that year
Phase 1
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
1 of 10
Alessa Therapeutics Inc.

Among the 10 studies in Lower Urinary Tract Symptoms with a site in Australia, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 5th registered.

Lower Urinary Tract Symptoms

417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

1 of the 10 studies in Lower Urinary Tract Symptoms with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 35 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lower Urinary Tract Symptoms with a site in Australia, or all of them as a file.
02

Study summary

Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether the Biolen is safe.

Read the detailed description

This prospective, multi-center, single-arm feasibility study is planned to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate in patients presenting for treatment of prostate cancer. Study participants will have placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy.

03

Conditions studied

  • Prostate Adenocarcinoma
  • Lower Urinary Tract Symptoms
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate.
  • Study participant qualified and planning for radical prostatectomy.
  • At least 1 prostate lesion measurable by MRI > 0.5 cm within one month of screening.
  • PSA > 3 ng/mL within 3 months of screening.
  • Gleason score 3+4 or higher.
  • Study participant must be willing to undergo post-treatment imaging by MRI.
  • performance status 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy or surgery for prostate cancer.
  • Prior or ongoing hormonal therapy for prostate cancer.
  • Prior prostate procedures such as transurethral resection of the prostate, transurethral microwave thermotherapy of the prostate, high-intensity focused ultrasound or minimally invasive BPH procedure.
  • Study participant unwilling or unable to undergo MRI, including patients with to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.
  • Metallic hip implant or any other metallic implant or device that distorts the quality of prostatic MR images.
  • Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of > 3 months.
  • Presence of any disease.
  • Prostate volume more than 80 cc at prior MRI imaging.
  • I-PSS score >20.
  • History of prostate infection.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Biolen

    Biolen bicalutamide implant. Single implantation. In situ until prostatectomy

    Combination Product: Bicalutamide implant

Interventions

06

What researchers measure

Primary outcomes

  1. Safety as measured by number and incidence of adverse events

    Adverse Events

    Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation

Secondary outcomes

  1. change in prostate size

    prostate measurement by MRI

    Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation

  2. change in tumor size

    tumor measurement by MRI

    Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation

  3. change in Prostate Specific Antigen (PSA)

    PSA level

    Time frame: change from baseline to radical prostatectomy up to 12 weeks after implantation

07

Study locations

4 sites
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
  • Australian Clinical Trials
    Wahroonga, New South Wales 2076, Australia
  • University of Wollongong
    Wollongong, New South Wales 2500, Australia
  • Tauranga Urology Research
    Tauranga, North Island 3112, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in May 2023, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2020
First posted
Feb 26, 2020
StartActual
Oct 11, 2020
Primary completionActual
May 3, 2023
CompletionActual
May 3, 2023
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04284761
Lead sponsor
Alessa Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 26, 2020
Start date
Oct 11, 2020
Primary completion
May 3, 2023
Completion
May 3, 2023
Last update
Jun 24, 2024

Study contacts

Pamela Munster, MD
study director · Alessa Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion